Research analysts at Stifel Nicolaus initiated coverage on shares of HilleVax (NASDAQ:HLVX – Get Rating) in a report issued on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.
Separately, JPMorgan Chase & Co. began coverage on HilleVax in a research note on Tuesday. They set an “overweight” rating for the company.
HLVX stock opened at $9.50 on Tuesday. HilleVax has a 52-week low of $9.00 and a 52-week high of $20.95.
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Featured Articles
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- Time to Bid Low for Farfetch Stock
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Don’t Wait Too Long to Buy These 3 Mega Caps
- Cheap Buys: These 3 Stocks are Now Trading Under $20
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
